Jan 19, 2022 (AB Digital via COMTEX) -- Investors were all spooked today with Dow plummeting more than 500 points. The primary cause can be attributed to inflation fears, disappointing earnings, and booming bond yields. Tech stocks drove the Dow down with the NASDAQ skidding 2.6 percent and the S&P 500 index falling 1.8 percent. The Dow closed down 1.5 percent. With the market selling off, it’s may very well be time to dive into biotech stocks currently trading at bargain prices. Some of the best value biotech stocks coupled with growth and momentum that needs to make the top of the Biotech Stock list include Brickell Biotech Inc /zigman2/quotes/205978721/composite BBI +7.29% , Intercept Pharmaceuticals Inc. /zigman2/quotes/202434567/composite ICPT +2.07% , Akebia Therapeutics Inc. /zigman2/quotes/206920525/composite AKBA +2.08% , uniQure NV /zigman2/quotes/203652599/composite QURE -28.64% , BioNTech SE /zigman2/quotes/214419716/composite BNTX -8.66% , Seres Therapeutics Inc. /zigman2/quotes/203151527/composite MCRB -3.61% , Marinus Pharmaceuticals Inc. /zigman2/quotes/208112000/composite MRNS +3.60% , Aadi Bioscience Inc. /zigman2/quotes/207167122/composite AADI +0.28% , Cassava Sciences Inc. /zigman2/quotes/204212356/composite SAVA +9.06% . During the past year, biotech stocks, as represented by the iShares Biotechnology ETF (IBB), have posted a total return of -12.8%, significantly below the Russell 1000's total return of 21.0% as of Jan. 13, 2022. However, 2022 could very well be a turning point for the biotech charts to run up.
A small-cap biotech company that is worth mentioning is Lexston Life Sciences /zigman2/quotes/229314234/composite LEXTF +67.91% . LEXTF had its Initial Public Offering in June of last year (2021), with an entry into the OTCQB Venture Markets and DTC-certification following just a few months later. Since then, the company has remained relatively “under the radar” while rapidly generating some early revenue through its subsidiary, Egret Bioscience. The company provides contact-based research for third parties, analytical testing services and stability testing. Their field of research includes the “God Molecule”
4 Key Advantages that Make Lexston Life Sciences a New Natural Leader:
The company’s Revolutionary Hybrid Business model is fueling organic growth from early revenue.
Newly DTC-Certified with a low float that could provide explosive moves on a daily basis when potential catalysts arise.
Driven by Elite Management Team with years of experience successfully navigating Canada’s tough regulatory framework.
Unrivaled Flexibility to Research and Develop new IP in Canada’s Rapidly-Growing Psy-che-delics industry.
5-meO-DM-T is often referred to as the “God Molecule,” for its ability to spark transcendental, transformative and religious experiences. Extracted from the Bufo alvarius toad from Mexico, it’s a powerful psy-che-delic believed to be effective in treating a variety of ailments like anxiety and depression. major medical research organizations like John Hopkins6 are delving deeper into the benefits than ever before. More than 6,000 different studies across 40,000 patients have now been completed, researching their effectiveness in treating everything from alcoholism and depression to schizophrenia and autism .
Remarkably, even just a few months after inception, the company is already generating revenues by monetizing its natural advantages in Canada’s red-hot market for psy-che-delics.
Through the company’s subsidiary, Egret Bioscience, the company has been completing research contracts, analytical testing, and retail tissue culture testing at an increasing rate—with enough projected income for 2022 to cover the year’s expenses.
One of the most compelling arguments for Lexston Life Sciences comes from just looking at the company’s financials and stock structure. As per otcmarkets.com , there are less than 60 million total shares, with the majority escrowed over the next three years. A full 20 million shares are presently restricted, limiting the maximum available float to just 36 million shares representing a cash total of less than $400,000 at today’s (1/6/22) prices.
Even for a small and relatively new company, that’s a practically miniscule amount of available exposure for any publicly-traded company. If and when the company books more contracts and boosts their revenue, that could lead to a substantial and swift upward swing due to the limited float and extreme low share price (presently at $.01 on the OTCQB on 1/6/22). ( Source )
Combined with the company’s already-steady revenues set to cover their expenses by the end of 2022, it’s a compelling argument to take a closer look at Lexston Life Sciences (otcmkts:LEXTF) /zigman2/quotes/227714303/delayed CA:LEXT -5.88% . Read more HERE
Disclaimer: Please make sure to completely read and understand our disclaimer at WallStreetPR.com/Disclaimer. We may be compensated for advertisement on LEXTF by a third party.
Is there a problem with this press release? Contact the source provider Comtex at firstname.lastname@example.org. You can also contact MarketWatch Customer Service via our Customer Center.